ES2079689T3 - Metodo para la fabricacion de una forma de dosificacion unitaria solida de liberacion controlada. - Google Patents

Metodo para la fabricacion de una forma de dosificacion unitaria solida de liberacion controlada.

Info

Publication number
ES2079689T3
ES2079689T3 ES91920733T ES91920733T ES2079689T3 ES 2079689 T3 ES2079689 T3 ES 2079689T3 ES 91920733 T ES91920733 T ES 91920733T ES 91920733 T ES91920733 T ES 91920733T ES 2079689 T3 ES2079689 T3 ES 2079689T3
Authority
ES
Spain
Prior art keywords
manufacture
controlled release
dosage form
unit dosage
solid unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91920733T
Other languages
English (en)
Inventor
Per Johan Gunnar Lundberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of ES2079689T3 publication Critical patent/ES2079689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of Vending Devices And Auxiliary Devices For Vending Devices (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

SE PRESENTA UN METODO PARA LA MANUFACTURA DE UNIDADES DE DOSIFICACION DE LIBERACION CONTROLADA QUE CONTIENE METILCELULOSA DE HIDROXIPROPIL EN LAS QUE SE REALIZA LA GRANULACION ACUOSA EN LA PRESENCIA DE UNA O MAS SUBSTANCIAS DISUELTAS, QUE INHIBEN LA FORMACION DEL GEL DURANTE LA GRANULACION PERO QUE PERMITEN LA FORMACION DE UN GEL CUANDO SE ADMINISTRAN ORALMENTE. TAMBIEN SE PRESENTAN NUEVAS UNIDADES DE DOSIFICACION PREPARADAS DE ACUERDO CON LA INVENCION.
ES91920733T 1990-12-07 1991-12-03 Metodo para la fabricacion de una forma de dosificacion unitaria solida de liberacion controlada. Expired - Lifetime ES2079689T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9003904A SE9003904D0 (sv) 1990-12-07 1990-12-07 Method for the manufacture of a pharmaceutical dosage form

Publications (1)

Publication Number Publication Date
ES2079689T3 true ES2079689T3 (es) 1996-01-16

Family

ID=20381123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91920733T Expired - Lifetime ES2079689T3 (es) 1990-12-07 1991-12-03 Metodo para la fabricacion de una forma de dosificacion unitaria solida de liberacion controlada.

Country Status (20)

Country Link
US (1) US5419918A (es)
EP (1) EP0560822B1 (es)
JP (1) JP3239319B2 (es)
AT (1) ATE130188T1 (es)
AU (1) AU659114B2 (es)
CA (1) CA2097175A1 (es)
DE (1) DE69114721T2 (es)
DK (1) DK0560822T3 (es)
ES (1) ES2079689T3 (es)
FI (1) FI932552L (es)
GR (1) GR3018685T3 (es)
HU (1) HUT64212A (es)
IE (1) IE914229A1 (es)
IS (1) IS3789A7 (es)
NO (1) NO932054D0 (es)
PL (1) PL168605B1 (es)
PT (1) PT99721A (es)
SE (1) SE9003904D0 (es)
WO (1) WO1992010169A1 (es)
YU (1) YU182091A (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3598049B2 (ja) * 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
DE69332081T2 (de) 1992-09-18 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelzubereitung mit verzögerter freisetzung
ES2059260B1 (es) * 1992-10-06 1995-04-16 Espanola Prod Quimicos Procedimiento de preparacion de comprimidos conteniendo diclofenaco; dispersables en agua.
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
JP2000034224A (ja) * 1998-05-11 2000-02-02 Freunt Ind Co Ltd 徐放性錠剤、その添加剤組成物及びそれらの製造方法
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
WO2003011256A1 (en) * 2001-07-30 2003-02-13 Sun Pharmaceutical Industries Limited Oral controlled release pharmaceutical composition of a prokinetic agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
AU2014255434B2 (en) * 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
EP0149186B1 (en) * 1983-12-20 1988-03-16 Tosoh Corporation Process for preventing agglomeration of powders
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
KR910002669B1 (ko) * 1986-12-25 1991-05-03 데이산세이야꾸 가부시끼가이샤 서방성 과립 및 그를 함유하는 지속성 복합과립
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition

Also Published As

Publication number Publication date
DE69114721T2 (de) 1996-04-18
HUT64212A (en) 1993-12-28
FI932552A7 (fi) 1993-06-04
AU8930991A (en) 1992-07-08
EP0560822B1 (en) 1995-11-15
PT99721A (pt) 1993-04-30
YU182091A (sh) 1994-04-05
SE9003904D0 (sv) 1990-12-07
IE914229A1 (en) 1992-06-17
HU9301672D0 (en) 1993-09-28
GR3018685T3 (en) 1996-04-30
FI932552A0 (fi) 1993-06-04
ATE130188T1 (de) 1995-12-15
CA2097175A1 (en) 1992-06-08
PL168605B1 (pl) 1996-03-29
JP3239319B2 (ja) 2001-12-17
WO1992010169A1 (en) 1992-06-25
FI932552L (fi) 1993-06-04
US5419918A (en) 1995-05-30
JPH06503310A (ja) 1994-04-14
IS3789A7 (is) 1992-06-08
NO932054L (no) 1993-06-04
DE69114721D1 (de) 1995-12-21
AU659114B2 (en) 1995-05-11
DK0560822T3 (da) 1996-03-11
PL299376A1 (en) 1994-03-07
EP0560822A1 (en) 1993-09-22
NO932054D0 (no) 1993-06-04

Similar Documents

Publication Publication Date Title
AR006652A1 (es) Forma farmacéutica de dosificación oral para el tratamiento oral de enfermedades óseas.
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ES2159591T3 (es) Composicion de liberacion controlada.
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
MX9203444A (es) Medicamentos.
AR032758A1 (es) Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
SE9003904D0 (sv) Method for the manufacture of a pharmaceutical dosage form
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
ES2173267T3 (es) Soluciones farmaceuticas salinas no inorganicas para la administracion endonasal de una calcitonina
UY27474A1 (es) Formulación de dosificación oral de fusion instantanea.
ES2176296T3 (es) Composiciones farmaceuticas que permiten la liberacion prolongada de trimetacidina despues de la administracion por via oral.
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
AR012504A1 (es) Utilizacion de derivados de tetrahidropiridina, para la preparacion de medicamentos para el tratamiento de las enfermedades que provocan unadesmielinizacion.
MX163553B (es) Metodo para preparar una forma de liberacion sustentada solida de una composicion funcionalmente activa
SE8901003D0 (sv) Snabbloesliga preparat
ES2054333T3 (es) Forma de dosificacion para administrar un antagonista del calcio.
ES2097952T3 (es) Comprimidos de liberacion programada que contienen naproxeno.
ES2075454T3 (es) Forma cristalina pura de rifapentina.
IT1151953B (it) Composizione farmaceutica per la cura di affezioni della cavita' orale
MX172107B (es) Procedimiento para la desinfeccion de masas para vaciado medicinales

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 560822

Country of ref document: ES